Pharmafile Logo
Pharmafocus logo
Advanced Search

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

September 13, 2023
Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …

News

FDA approves LimFlow system for patients with CLTI

September 13, 2023
Medical Communications CLTI, Devices, FDA, LimFlow

LimFlow SA has announced that the US Food and Drug Administration (FDA) has approved its LimFlow System for the treatment …

News

NHS-integrated pharmacy app Charac receives £1.2m funding

September 12, 2023
Research and Development Charac, Pharmacy, app, digital health, pharmacies

Charac, an NHS-integrated pharmacy app, has raised £1.2m in debt and equity financing from the National Pharmacy Association (NPA) and …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

News

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

News

Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America

September 11, 2023
Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab

Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …

News

CymaBay shares results from phase 3 RESPONSE trial for seladelpar

September 8, 2023
Research and Development CymaBay, PBC, Pharmacy, clinical trial, seladelpar

CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …

News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

Vaxart shares topline data from phase 2 study of norovirus vaccine candidate

September 8, 2023
Research and Development Infections and infestations, Vaccine, Vaxart, norovirus

Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …

News

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023
Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …

News

BridgeBio Pharma shares positive feedback from FDA and EMA for phase 3 trial of infigratinib

September 7, 2023
Research and Development BridgeBio Pharma, EMA, FDA, Musculo-skeletal disorder, achondroplasia, clinical trial

BridgeBio Pharma has announced positive feedback from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on …

News
towfiqu-barbhuiya-msqb97guxy0-unsplash

Abbott to acquire Bigfoot Biomedical

September 6, 2023
Business Services Abbott, Bigfoot Biomedical, Diabetes, acquisition, diabetes

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …

News

Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase

September 6, 2023
Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase

Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …

News
headache

AbbVie’s Aquipta receives MHRA marketing authorisation

September 5, 2023
Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …

News

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

September 5, 2023
Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …

News

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023
Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …

News

Novo Nordisk launches Wegovy in the UK

September 4, 2023
Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …

News
lungs

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

News
hal-gatewood-_jbclosdsd4-unsplash

FDA approves new ADHD and BED generics

September 1, 2023
Medical Communications BED, FDA, Pharmacy, generic medicines

The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …

News

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023
Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …

News

Twist Bioscience and Ono Pharmaceutical enter agreement for discovery of novel antibodies

August 31, 2023
Research and Development Immunology, Ono Pharmaceutical, Twist Bioscience, antibodies, autoimmune diseases

Twist Bioscience has announced that it has entered a drug discovery agreement with Ono Pharmaceutical for the discovery and development …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025